Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

Central to the upgrade is a deep dive into asundexian, Bayer’s oral Factor XIa inhibitor, which is currently in a Phase III trial for secondary stroke prevention. Results are expected in the ...

Successful drug development is imperative to Bayer amid multiple challenges. The failure of a late-stage study on asundexian was a major setback for the company. BAYRY is also working to expand ...

Overall, asundexian was associated with a lower risk ... This study was supported by Bayer AG, Leverkusen, Germany. Alexander reported receiving grants, honoraria, or consulting fees from various ...

BofA Securities has raised its rating on Bayer (ETR: BAYGN) to “buy” from “neutral,” increasing its price objective to €30 ...